Q-omics provides the consensus-scored RPL17P40 profile across patient tissues and cancer cell-line models. RPL17P40 expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, RPL17P40 is differentially expressed in 3, with the highest sampling consensus in UCEC. Additionally, RPL17P40 RNA expression shows 11,071 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRC, UCEC, and LSCC as cancer lineages where RPL17P40 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPL17P40 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPL17P40 survival associations across molecular data types. RPL17P40 RNA expression shows survival associations in the most cancer types (17). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPL17P40 RNA expression–survival associations across cancer types. High RPL17P40 expression shows unfavorable associations in KIRC, THCA and ACC, but favorable associations in LUAD, BLCA and COAD. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for RPL17P40 RNA expression.
This table summarizes RPL17P40 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for RPL17P40. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPL17P40 shows lower tumor expression in THCA and higher tumor expression in UCEC and COAD. The UCEC box plot shows higher RPL17P40 RNA expression in tumor versus normal tissue (log2 FC = +0.450, t-test p = .012).
This table shows molecular features associated with RPL17P40 in patient tissues and cancer cell lines. In patient samples, RPL17P40 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set.
